BCIQ Profiles

Company Profile Report

ORIC’s CD73 inhibitor for cancer; plus Beam, CRISPR-Cas13 for respiratory infections, COVID-19 complex structure, and more

BioCentury’s roundup of preclinical news

Small molecule CD73 inhibitor for cancer

A small molecule CD73 inhibitor from ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) has shown significant antitumor activity in vivo. ORIC-533 is slated for an IND submission in 1H21. CD73, which is overexpressed in cancers including melanoma and triple negative breast, non-small cell lung and prostate cancers, controls adenosine production; adenosine accumulation is implicated in immune suppression

Read the full 609 word article

How to gain access

Continue reading with a
two-week free trial.